Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

498
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498
Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib.

Frontiers in molecular biosciences·2026
Same author

Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.

The Lancet. Oncology·2026
Same author

The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Nature biomedical engineering·2026
Same author

Evaluating the Role of Chemotherapy in Addition to Radiotherapy for High-Risk Merkel Cell Carcinoma.

Medical sciences (Basel, Switzerland)·2026
Same author

Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).

Cancer immunology, immunotherapy : CII·2026
Same author

Risk-adapted SBRT ([Formula: see text]) for recurrent lung-only metastases in patients with frailty or ultracentral anatomy.

Radiation oncology (London, England)·2026

Related Experiment Video

Updated: Jun 19, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report.

Ofra Maimon1, Benjamin Nisman2, Shani Broier1

  • 1Department of Oncology, Hadassah and Hebrew University Medical Centre, Jerusalem, Israel.

Anticancer Research
|July 26, 2024
PubMed
Summary

Combining CDK4/6 inhibitors with tumor vaccination shows promise for metastatic breast cancer (MBC). This approach can enhance anti-tumor immunity, but careful immune microenvironment regulation is crucial for success.

Keywords:
CDK4/6 inhibitorsCOVID-19 vaccinationMetastatic breast cancercancer vaccinationcytokinesthymidine kinase 1

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.1K

Related Experiment Videos

Last Updated: Jun 19, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.1K

Area of Science:

  • Oncology
  • Immunotherapy
  • Breast Cancer Research

Background:

  • Metastatic breast cancer (MBC) standard treatment includes cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy.
  • These therapies have shown potential in augmenting anti-tumor immune responses.

Observation:

  • A clinical case involved co-administering palbociclib and letrozole for MBC.
  • Allogeneic tumor vaccination was integrated into this regimen.
  • The COVID-19 vaccine negatively impacted the anti-tumor immune response.

Findings:

  • Tumor vaccination heightened interferon-γ production and expanded CD8+ and NK cell populations.
  • This led to positive delayed-type hypersensitivity reactions, indicating successful anti-tumor immunity development.
  • The patient achieved 42 months of progression-free survival.

Implications:

  • Combining active tumor vaccination with CDK4/6 inhibitor therapy is a feasible strategy for MBC.
  • Careful regulation of the tumor microenvironment is critical for optimizing treatment outcomes.
  • This approach warrants further investigation in metastatic breast cancer management.